GLP-1 reduces the blood glucose by stimulation of insulin secretion; thus, the inhibitors of DPP-4 that reduced the GLP-1 cleavage are used for type 2 diabetes treatment [15, 16]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.